Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.78 · Revenue $0.00 · 1 analysts
Est. EPS $-0.87 · Revenue $0.00 · 1 analysts
Est. EPS $-9.84 · Revenue $0.00 · 1 analysts
Est. EPS $-0.42 · Revenue $0.00 · 1 analysts
EPS $-0.89 · Revenue $0.00
EPS $-1.87 · Revenue $0.00
EPS $-0.24 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-12.9M | -31.1% | +18.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-8.5M | -2.0% | -322.6% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -53.3% | -1564.3% | -90.9% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.17x | -88.1% | +68.0% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $2.8M | -40.4% | -48.4% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -49.23 vs -36.33 | -35.5% | -0.89 vs -0.78 | -14.1% |
| Revenue Surprise | — | — | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | MATSUI CONNIE | director | Stock Option (right to buy) | A | 136 | $1.15 |
| Jul 17, 2026 | Blayney Douglas | director | Stock Option (right to buy) | A | 136 | $1.15 |
| Jul 17, 2026 | Reyes Gregory | director | Stock Option (right to buy) | A | 136 | $1.15 |
| Jul 17, 2026 | EMANUELE ROBERT MARTIN | director | Stock Option (right to buy) | A | 136 | $1.15 |
| Jul 17, 2026 | Kelly Steven | director | Stock Option (right to buy) | A | 136 | $1.15 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Gregory D. Gorgas | President, Chief Executive Officer, Secretary & Director | USD 876,923 | Male | 1963 | Active |
Mark E. Spring | Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer | USD 225,980 | Male | 1959 | Active |
Andrew Yates | Senior Vice President & Chief Scientific Officer | — | — | — | Active |
Steven D. Reich | Chief Medical Officer | — | — | 1946 | Active |
Jason H. Baybutt | Senior Vice President of Finance | — | Male | 1972 | Active |
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 85,320 shares, a decline of 36.9% from the July 30th total of 135,122 shares. Currently, 1.9% of the shares of the company are sold short. Based
Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026
SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company's patent application covering the intended commercial formulation of ART27.13, Artelo's peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials.
The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent application covering the intended commercial formulation of ART27.13, the Company's peripherally selective cannabinoid agonist currently being evaluated in the Phase 2 CAReS trial for cancer-related anorexia and the Phase 2 DREAM study in patients with glaucoma or ocular hypertension.
SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the second quarter ended June 30, 2026.
